18 August 2020Big PharmaMuireann Bolger

Novartis secures victory as MS drug patent is upheld

In a win for Novartis Pharmaceuticals, the US District Court for the district of Delaware has upheld the patent on its top-selling multiple sclerosis drug Gilenya.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

AbbVie fights to invalidate Novartis patents

3 April 2017 AbbVie has filed a declaratory judgment against Novartis, alleging that its patents covering the treatment of hepatitis C virus are invalid.

Americas

Novartis tries to block generic versions of Gilenya, enforces new patent

30 January 2020 Swiss pharmaceutical giant Novartis is trying to stop an array of drugmakers manufacturing and selling generic versions of its newly-patented multiple sclerosis treatment, Gilenya.

Big Pharma

Novartis MS drug appeal upheld in Australia

13 October 2020 The Federal Court of Australia has backed Novartis’ appeal against a decision revoking its patent covering a multiple sclerosis drug.

More on this story

Americas

AbbVie fights to invalidate Novartis patents

3 April 2017 AbbVie has filed a declaratory judgment against Novartis, alleging that its patents covering the treatment of hepatitis C virus are invalid.

Americas

Novartis tries to block generic versions of Gilenya, enforces new patent

30 January 2020 Swiss pharmaceutical giant Novartis is trying to stop an array of drugmakers manufacturing and selling generic versions of its newly-patented multiple sclerosis treatment, Gilenya.

Big Pharma

Novartis MS drug appeal upheld in Australia

13 October 2020 The Federal Court of Australia has backed Novartis’ appeal against a decision revoking its patent covering a multiple sclerosis drug.

More on this story

Americas

AbbVie fights to invalidate Novartis patents

3 April 2017 AbbVie has filed a declaratory judgment against Novartis, alleging that its patents covering the treatment of hepatitis C virus are invalid.

Americas

Novartis tries to block generic versions of Gilenya, enforces new patent

30 January 2020 Swiss pharmaceutical giant Novartis is trying to stop an array of drugmakers manufacturing and selling generic versions of its newly-patented multiple sclerosis treatment, Gilenya.

Big Pharma

Novartis MS drug appeal upheld in Australia

13 October 2020 The Federal Court of Australia has backed Novartis’ appeal against a decision revoking its patent covering a multiple sclerosis drug.